4/9
03:35 pm
dsnky
FDA Roundup: April 9, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: April 9, 2024 [Yahoo! Finance]
4/5
09:52 pm
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yahoo! Finance]
4/5
04:21 pm
dsnky
AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications [Seeking Alpha]
Low
Report
AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications [Seeking Alpha]
4/5
04:05 am
dsnky
AstraZeneca Says Key Lung Cancer Drug Improved Survival [BNN Bloomberg (Canada)]
Low
Report
AstraZeneca Says Key Lung Cancer Drug Improved Survival [BNN Bloomberg (Canada)]
3/22
11:37 am
dsnky
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events [Yahoo! Finance]
Low
Report
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events [Yahoo! Finance]
3/12
09:43 am
dsnky
Lung Cancer Research Foundation Announces Research Grant Awards [Yahoo! Finance]
Low
Report
Lung Cancer Research Foundation Announces Research Grant Awards [Yahoo! Finance]
3/5
09:03 am
dsnky
Breast Cancer Drug Won't Be Offered to 1,000 Patients in England [BNN Bloomberg (Canada)]
Low
Report
Breast Cancer Drug Won't Be Offered to 1,000 Patients in England [BNN Bloomberg (Canada)]
3/4
02:00 am
dsnky
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
Low
Report
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
2/7
09:36 am
dsnky
QuantHealth Appoints Dr. Adam Petrich, MD, As Its First Chief Medical Officer and Adam Goldberger As First Chief Financial Officer [Yahoo! Finance]
Low
Report
QuantHealth Appoints Dr. Adam Petrich, MD, As Its First Chief Medical Officer and Adam Goldberger As First Chief Financial Officer [Yahoo! Finance]
1/29
02:00 am
dsnky
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Low
Report
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors